Navigation Links
Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer

MARSEILLE, France, May 19 /PRNewswire/ -- IPSOGEN SA (Marseille and New Haven), a cancer profiler that develops and markets molecular diagnostic assays for blood & breast cancers, announced today that researchers from the University of Texas MD Anderson Cancer Center (MDACC, Houston, TX) will present the results of two studies on the Genomic Grade index (GGi) at the ASCO Annual Meeting, held in Chicago from May 30 to June 3, 2008. The data indicate that the Genomic Grade index predicts response to chemotherapy in breast cancer. A third study extends the pronostic utility of the GGi to inflammatory breast cancer.

The Genomic Grade index (GGi) is a 97-gene measure of tumor grade, a key prognostic indicator of breast cancer agressiveness closely related to cellular proliferation. Ipsogen is the exclusive worldwide licensee of the GGi technologies.

Two MD Anderson Cancer Center studies

In a preliminary study published in May 2008 in Breast Cancer Research (1) conducted on 133 patients, MDACC researchers had found that, among 852 genomic indexes describing biological pathways, the GGi was one of the most promising candidate for predicting response to chemotherapy.

In the first study to be presented (abstract 541, (2)), Dr. Symmans and colleagues from MDACC and Institut Bordet (Brussels, Belgium) validated the GGi as a predictive marker of chemotherapy response in 229 patients with HER2-normal breast cancer. All patients were treated with a current standard chemotherapy regimen, T/FAC (6 months of paclitaxel followed by 5-fluoruracil, doxorubicin, and cyclophosphamide) then by surgery. In such preoperative chemotherapy settings, treatment efficacy can be rapidly & precisely assessed by examining the resected tumor in a pathology laboratory.

This study concludes that high GGi is predictive for increased sensitivity to T/FAC chemotherapy in both ER- and ER+ patients. In addition, the GGi can be combined with ER and nodal status to predict which patients will not respond to preoperative T/FAC chemotherapy in 72 % of cases.

"This work demonstrates that high genomic grade, as a robust measure of proliferation in the tumor cells, is associated with benefit from chemotherapy. In the context of other published work it underlines the association between high tumoral proliferation rate and chemosensitivity, endocrine insensitivity and worse prognosis" comments Dr. Symmans, associate Professor of Pathology at the MDACC.

"This study is a straightforward demonstration of the clinical utility of the Genomic Grade index for predicting response to chemotherapy. It also highlights the ongoing commitment of the oncology community to validate new molecular assays that strongly connect with the breast tumor biology and fit within the pathologist's practices" comments Dr. Jean-Marc Le Doussal, Director of Breast Cancer Program at Ipsogen.

Visit Ipsogen booth 23128 at the 44th ASCO annual meeting

In the second study to be presented (abstract 527, (3)), Dr. Pusztai and colleagues showed a pionnering application of multi-testing on genome-wide microarrays by combining the GGi, for the prediction of chemotherapy response, with the 200-gene endocrine-sensitivity index, for the prediction of hormonotherapy response.

"This study further confirms the potential of Ipsogen's pipeline strategy of multiple high-resolution genomic measurements to improve the decision tree of chemotherapeutic options in breast cancer>> says Vincent Fert, CEO of Ipsogen. "We are fully committed to rapidly translate these clinical findings into regulatory-approved and reimbursed test offering to European and American patients," he adds.

One University of Antwerp study

A third study (abstract 11048, (4)), presented by Dr. Van Laere from Antwerp University, Belgium, validates the pronostic value of the GGi in inflammatory breast cancer, an aggressive type of breast cancer affecting a few percent of patients.


Ipsogen is a cancer profiler that develops and markets molecular diagnostic assays designed to map diseases and guide patients and clinicians decisions along the complex therapeutic path.

With more than 60 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. Its initial goal will be to provide diagnostic information that has been inaccessible until now. Ipsogen is also a partner of choice for biopharmaceutical companies committed to revolutionary theranostics.

Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly-skilled multidisciplinary team in France and the US, Ipsogen is striving to become the leader in the molecular profiling of cancers. It is pursuing its development and promotion of diagnostic standards that have a significant impact on patients, medical professionnals and society in general.

Ipsogen employed 40 people as of April 30,2008. Its headquarters are located in Marseille, France. The company also has a subsidiary, Ipsogen Inc., in New Haven, Connecticut, USA.

Find out more at


(1) Tordai A, Wang J, Andre F, Liedtke C, Yan K, Sotiriou C, Hortobagyi GN, Symmans FW, Pusztai L. Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Research 2008, 10:R37.

(2) W. F. Symmans, C. Hatzis, C. Liedtke, C. Desmedt, V. Valero, H. M. Kuerer, G. N. Hortobagyi, M. Piccart-Gebhart, L. Pusztai, C. Sotiriou. Use of genomic grade index (GGI) to predict pathologic response to preoperative chemotherapy in breast cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 541).

(3) L. Pusztai, C. Hatzis, F. Cardoso, C. Sotiriou, V. Lazar, M. Piccart-Gebhart, G. N. Hortobagyi, L. van't Veer, W. F. Symmans. Combined use of genomic prognostic and treatment response predictors in breast cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 527).

(4) S. J. Van Laere, G. G. Van den Eynden, I. Van der Auwera, X. B. Trinh, P. A. van Dam, E. A. Van Marck, P. B. Vermeulen, L. Y. Dirix. Inflammatory breast carcinoma signature and relapse-free survival in patients with noninflammatory breast cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 11048).

SOURCE Ipsogen
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Thanks to a ... Health St. Mary,s Medical Center,s Sister Diane Grassilli Center ... imaging capabilities in San Francisco . ... anonymous friend, stepped forward with a gift of $617,320 ... Breast Digital Mammography with Tomosynthesis and Whole Breast Ultrasound. ...
(Date:11/24/2015)... 2015  In the pharmaceutical industry, companies want to ... quickly uncover new insights, tactics and strategies that will ... --> However, organizations often find it is ... ensure that all rules and regulations are met to ... barrier to efficiently launching market research projects is the ...
(Date:11/24/2015)... York , 24. November 2015 /PRNewswire/ ... Avery Breathing Pacemaker Systems, ist erfreut, die ... Clinical Consultant bekannt geben zu können. ...   --> Foto - ... (Schweden). Von 1984-1986 war er ...
Breaking Medicine Technology:
(Date:11/25/2015)... Jacksonville, FL (PRWEB) , ... November 25, 2015 ... ... treatment center, is encouraging people across the country to celebrate their sobriety and ... invites people to post “before and after” photos this Thanksgiving with the hashtag ...
(Date:11/25/2015)... Lake, IL (PRWEB) , ... November 25, 2015 , ... ... to announce a recent successful appellate decision obtained by Attorneys Francisco J. Botto and ... case Adcock v. Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Beddit® has ... Beddit Classic sleep tracking systems. The new app features a more intuitive SleepScore™ that ... understand how well you slept. The SleepScore is created by a proprietary algorithm. Beddit ...
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk Driving (MADD) ... below 10,000 for the first time since 2011. In 2014, there were 9,967 fatalities ... released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in ...
(Date:11/25/2015)... Davie, Florida (PRWEB) , ... November 25, 2015 ... ... PharmaTech LLC has announced that it has undertaken significant expansion of its current ... Florida. The investment is part of PharmaTech’s strategy to increase its manufacturing capacity ...
Breaking Medicine News(10 mins):